In this paper we present a mathematical analysis of the four classical indirect response models. We focus on characteristics such as the evolution of the response R(t) with time t, the time of maximal/minimal response
INTRODUCTION
The re-introduction of the turnover models (1) (2) (3) by Jusko and colleagues in the early 90s (4), the extension of those to the feedback situation (5, 6 ) and integrating receptor-interaction models with feed-back governed turnover models (7, 8) have rejuvenated the field of mechanism-based pharmacodynamic modeling.
The turnover model, more recently also called the indirect response model, provides a unique tool for the pharmacokineticists, in that it logically combines features of pharmacokinetics with pharmacodynamics. It clearly distinguishes drug properties (such as EC 50 ) from system properties (k out and k in ). The turnover model is applicable to a wide range of modeling situations, ranging from modeling homeostatic features of the water balance to induction of metabolic enzymes, and pharmacological responses (see Refs. (9) and (10) for a mini review). Few researchers have during recent years so elegantly laid out the mathematical properties of this class of models and exemplified their use as Jusko and co-workers have done in a series of papers (cf. (11) (12) (13) (14) (15) ).
When the pharmacological response takes time to develop, and the observed response is not instantaneously related to plasma concentration of the drug, a model for this time-delay has to be incorporated. Currently, there are at least three conceptually different approaches to capture this time-delay, namely biological/mechanistic, empirical/distributional, and receptor on/off rate models. When the time delay then has been assumed to be of distributional origin, a first-order effect-compartment (or link) model has been applied. Provided first-order plasma kinetics, a prerequisite has been a dose independent T max value for experimental response data. If this is not the case a turnover (or indirect, response) model has often been shown to be the solution. In other words, peakshift or no peak-shift has become a discriminative tool for selection of the class of model. Unfortunately, lack of peak-shift with increasing doses has implied an effect-compartment model and a peak-shift has implied a turnover model by some investigators (16) .
The indirect response models are constructed from a function describing the plasma kinetics, a drug mechanism function relating plasma kinetics to the type of mechanistic action (inhibition I max /I C 50 or stimulation E max /EC 50 ), and the turnover rates k in and k out ). Provided linear kinetics, the pharmacokinetic function per se will not contribute to a peak-shift in the pharmacological response. Also, the turnover function behaves linearly with proportional changes of the turnover rate. What is left, as a potential source of this peak-shift, is then the drug mechanism function. Simulations have shown that a peak shift may or may not occur with increasing doses, and that they can be toward earlier as well as later times (9) . The aim of this paper is to cast light on this phenomenon from a mathematical analytical point of view and to make general statements about the dynamics that may be useful for model discrimination and experimental design purposes.
Specifically, we have two objectives:
I Establish qualitative properties of the response curves of turnover models. Specifically, we derive upper and lower bounds for the size of the response, for the time of maximal response, or Peak Time, T max and we obtain estimates for the behavior of these quantities as the drug dose becomes large. Many of these properties have been established before. The novelty will be, however, that here these properties will be derived by qualitative methods which involve a geometric analysis of the turnover equation based on the theory of dynamical systems (17) . An important feature of this approach is that it can also be used for the analysis of nonlinear generalizations of the basic linear turnover models and for more complex pharmacodynamic systems.
II Study the dependence of T max , on the drug dose, and determine the influence of the parameters and the drug mechanism functions involved. To that end we present an asymptotic analysis for small and large drug doses, and a numerical study to cover the range of intermediate values of the drug dose.
The outline of this paper is the following. After an introduction of the different types of turnover models, we first present the main analytical results about the response curves and the Peak Time T max . To complete the picture, we present the outcome of a series of numerical simulations. We then turn to a detailed qualitative analysis of the turnover equations and an asymptotic analysis of the peak time T max (D) for small and large values of the drug dose. Some indications are then given of generalizations of these results to more general drug functions and to nonlinear versions of the turnover equation. Finally, we present a discussion and offer some conclusions of the methods we used and the results we established in this paper. We end this paper with a series of appendices in which the more delicate mathematical arguments, needed to prove our results, are presented.
For the numerical rendering of solution graphs we have used the ODE solver XPPAUT (18) and for the graphs of the Peak Time versus the drug dose we used the package Maple 9 (19).
TURNOVER MODELS
In the basic linear turnover model the pharmacological response R(t) is governed by the equation
in which the turnover rate k in and the fractional turnover rate k out are the rate constants involved in the zeroth order gain term and the first order loss term, respectively (20) . The action of the drug takes place through the drug mechanism function H(C), where C = C(t) is the plasma concentration of the drug as a function of time (the drug function) (3, 4) . This action may take place either via the gain term k in , in which case Eq. (1) becomes
or via the loss term k out , when
We consider two types of drug mechanism functions: those which inhibit and so reduce the effect of either the gain or the loss term:
and those which stimulate and increase the effect of the gain or the loss term:
Here the symbol def = means that the quantity on the left is defined to be the quantity on the right. Since the drug mechanism function needs to be positive, we will require that 0 < I max ≤ 1. An important feature of these drug mechanism functions is their boundedness;
In addition to these nonlinear, saturating drug mechanism functions we will discuss results for the linear functions I (C) = 1 − αC and S(C) = 1 + αC (5) in which α is a positive constant. They can be viewed as approximations of the nonlinear functions when C I C 50 or C EC 50 . In the case of inhibition we must require that α and C are so small that I (C) remains positive. Fig. 1 . Schematic illustration of the four turnover models. The models I and II represent inhibition I (C) of, respectively, the turnover rates k in and k out , and the models III and IV represent stimulation S(C) of these turnover rates(4).
In this paper we focus on four different linear turnover models: two models in which the turnover rates k in and k out are inhibited; we denote these models by Model I and Model II. In the other two models these turnover rates are stimulated. They will be called, respectively, Model III and Model IV (4). We do this for the nonlinear, as well as for the linear drug mechanism functions given in Eqs. (3)- (5) . The four models are shown schematically in Fig. 1 .
Since the emphasis in this paper is on the dynamics of the four turnover models, we will often assume a very simple drug function:
where k is the elimination rate and D a positive constant which is a measure for the amount of drug that has been administered. We shall call it the Drug Dose. The volume of distribution is set equal to unity. Many of the methods used in this paper can also be applied when the drug function is more complex. As an example we shall discuss the dynamics of the turnover models when the drug function is the Bateman function, which mimics a first order input (k a )− output (k) process:
When no drug is present, i.e. when D = 0 and hence H = 1, the Eqs. (2a) and (2b) reduce to Eq. (1). This equation has a unique equilibrium state, often referred to as the Baseline: (8) and any solution R(t) converges to R 0 as t → ∞. Henceforth we assume that the system is in this state when, at t = 0, the drug is administered, i.e.
When a drug has been given, and the plasma concentration is given by Eq. (6) or Eq. (7), the response R(t) is determined by the differential equation (2a) or (2b) together with the initial value given by Eq. (9) . We shall show that in the models I and IV, the response decreases monotonically after administration, reaches a minimum, and then increases monotonically to the initial state R 0 . In the models II and III the order is reversed: the response first rises to a maximum and then drops monotonically back to the initial state. In Fig. 2 we show four typical sets of graphs of R(t).
The time at which the response R(t) reaches its extreme value, either a minimum or a maximum, will be called T max . We shall often refer to it as the Peak Time. We shall be interested to learn how T max depends on the drug dose D, and derive qualitative properties of the response curves in the four models, both for nonlinear and for linear drug mechanism functions. Many of the methods used in this paper are qualitative, and can also be applied to nonlinear turnover models, such as described by the equation
in which the loss term saturates and k in , k out and R 50 are positive constants (cf. (21, 22) ). At the end of this paper we shall obtain some qualitative results for this nonlinear model.
THE PEAK TIME T max
In this section we first present a series of analytical results about the way the response R(t) and the peak time T max depend on the drug dose D. We begin with a few qualitative observations and then present the behavior of T max for small and large doses. To complete the picture, we give in the next section numerically computed graphs of the function T max (D) for the four different models I-IV, both when H is nonlinear, and when it is linear.
Dimensionless Variables
The basic equations (2a) and (2b) feature a range of constants: the turnover-related rates k in and k out , the kinetic constants I max , I C 50 and E max , EC 50 , and finally the constants in the drug function: the drug dose D and the elimination rate k. It is then useful to introduce dimensionless variables. By doing so we achieve two objectives:
• Different constants combine into a smaller number of dimensionless parameters, each endowed with a physiological meaning.
• The resulting equations are simpler and thereby more transparent.
Let us introduce the following dimensionless variables:
Thus, the new dimensionless time t * compares physical time with the characteristic time (1/k) of the elimination of the drug, and the new dimensionless response R * (t) compares the response R(t) to the equilibrium response R 0 in the absence of a drug. Finally, the new dimensionless parameter κ compares the decay rate k out of the response in the absence of a drug, to the elimination rate k of the plasma concentration.
We also scale the concentration, and set
depending on whether the drug inhibits or stimulates. In terms of these new variables, Eqs. (2a) and (2b) become
where
, and the new drug mechanism functions I * and S * are given by
in which α = I max in I * and α = E max in S * . When the drug mechanism functions are linear they become
The initial value of the response R, and the drug function C have become
where we have scaled D like we scaled C in Eq. (12), i.e., D * = D/I C 50 or D * =D/EC 50 . Thus, we have now reduced the original problem to one in which the relevant parameters are the relative turnover rate κ, the constant α in the drug mechanism functions, and the drug dose D * , i.e., these three parameters completely determine the dynamics of the turnover model. This implies in particular that the dynamics is not so much determined by the drug dose alone, but by its relation to I C 50 or EC 50 , i.e., if I C 50 or EC 50 is small then even a small drug dose can have a large impact.
Pharmacodynamic Properties
We are now ready to formulate a series of general properties of the dynamics of the response R(t). In Properties A-E we impose only global conditions on the drug function C(t). In Property F we assume that C(t) is given by Eq. (6).
Property A. When the plasma concentration C(t) vanishes as t → ∞, then the response returns to the baseline value:
This means that there will be no residual effect, i.e., when the drug leaves the body, the body returns to its original state. We prove that the turnover models I-IV all have this property.
Property B.
Suppose that the drug function C(t) is either decreasing, or first increasing and then decreasing, and the drug mechanism functions I (C) and S(C) are given by Equations (3) and (4) or (5), then the graph of R(t) has precisely one critical point: a minimum in models I-IV, and a maximum in models II and III.
Property C. Let C(t) be an arbitrary drug function. When the drug mechanism functions I (C) and S(C) are nonlinear, and given by Eqs. (3) or (4), we have the following bounds, which are independent of the drug dose: The Properties A-E are not all new. We mention in particular the Refs. (10) (11) (12) (13) (14) (15) and (23) , where many of them were established. In these studies essential use was made of the fact that it is possible to solve the equations for R(t) explicitly. A drawback of this method is that the resulting expressions can get very involved, especially when the drug function becomes complex. In such cases the explicit solution yields little qualitative insight into the dynamics of the process. Another limitation of this method is that it is mainly restricted to linear equations.
In this paper we adopt a different approach and prove the properties A, B, C, D and E by using qualitative, and geometric arguments which are familiar in the theory of dynamical systems. Such an approach is conceptually attractive since it readily gives insight in the dynamics of the problem. In addition, this approach can be used to study linear and nonlinear problems alike.
In a similar spirit, we derive simple expressions for R(t) and T max when the dose is either small or large. In order to keep the formulas transparent we will phrase the following results in terms of the dimensionless variables introduced in Eqs. (11) and (12) . However to avoid a plethora of asterisks, we will retain the original notation.
From now on we assume that C(t) is given by Eq. (6), i.e., in dimensionless variables, by
Small doses. We note that when we expand the nonlinear functions I (C) and S(C) in powers of C, we find that
i.e., the first two terms on the expansion agree with the linear drug mechanism functions. 5 In fact, we find that for all the four turnover models I-IV -whether nonlinear or linear -the peak time T max . converges to the same positive value as the drug dose becomes small: 5 For the definition of the symbol O, see the list of symbols at the end of this paper.
The limiting value T 0 is given by
Recall that when κ = 1 the decay rate k of the drug function is the same as the fractional turnover rate k out .
In the question as to whether the peak time is delayed, advanced or unchanged when a small amount of the drug is given, the models differ. This question can be answered by computing the slope with which the graph of T max (D) intersects the vertical axis D = 0: if the slope is positive then T max (D) increases with increasing drug dose, whilst if the slope is negative it decreases with increasing drug dose (cf. Figs. 5, 6 and 7). We find the following expression when I and S are nonlinear:
The constants
Note that L 1 and L 2 only depend on the value of κ = k/k out . It turns out that
Thus we have established the following property:
Property F. In the models I, II and III the peak time increases whilst in the model IV the peak time decreases for small increasing drug dose, provided E max , or α, is large enough. Specifically, we then require
Remark . Note that Eq. (17) states that in the models I and III, at D = 0 the slope of the graph of the function T max (D) only depends on the value of κ and not on the value of α. This was observed before in (11) and (12) . When I (C) and S(C) are linear, then from Property D we conclude that in the models I and III dT max /d D(D) = 0 for all D > 0. For the models II and IV we show that
Thus, in model IV the peak time comes earlier, whilst in model II it comes later when a small dose is given. For details of the derivation of these limits, we refer to the section on asymptotics. Large doses. Here, there is an important difference between the nonlinear and the linear drug mechanism functions. Nonlinear drug mechanism functions. We shall see in the section on qualitative analysis that in each of the four models, for fixed t:
where R(t) denotes the lower bound (in models I and IV) or the upper bound (in models II and III) defined in Property C. It is strictly monotone function: decreasing in the models I and IV and increasing in the models II and III. This means that in each model T max (D) → ∞ as D → ∞. Specifically, we prove that
where K (κ, α) is a positive constant, which depends on κ and α, and on the model. A qualitative argument shows that K (κ, α) ≤ 1 fo r all κ > 0 and α > 0 (α ≤ 1 in the models I and II). 6 In Fig. 3 we show the response curves for increasing values of the drug dose, and we see what looks like a progressing wave: the maximum of the response no longer increases, and approaches the value 1 + α, but the duration of the response grows with a rate which is proportional to log(D). In the section on qualitative analysis we shall show that in the limit, the shape of this wave no longer changes in suitably moving coordinates. 6 For the definition of the symbol ∼, see the list of symbols at the end of the paper. 
where (s) is a monotone function defined on s ∈ (−∞, ∞): decreasing in the models II and III and increasing in the models I and IV. In a qualitative analysis we prove Eqs. (19) and (20), and we give an expression for the limiting shape (s). In the special case, when in model II we take α=1, the upper bound R(t) is not a bounded function, but one that grows linearly as t → ∞. For this case we find a different type of wave phenomenon, which is shown in Fig. 4 . Linear drug mechanism functions. In the linear models there are no comparable uniform upper or lower bounds for the response:
• In models I and III, in which the gain is either stimulated or inhibited, the magnitude of the response is proportional to D, and T max , does not move. • In model IV, in which the loss is stimulated, the response always stays positive, and we find that T max decreases with increasing drug dose. Specifically we show that
In model II the concentration is restricted, since we require that I (C) = 1 − αC ≥ 0. Hence, this model is of no practical interest for large drug doses. Details of the small and the large dose asymptotics are given in the section on asymptotics.
NUMERICAL RESULTS
In order to gain further insight into the question of monotonicity we have computed T max (D) numerically in the four models, when I (C) and S(C) are nonlinear (hyperbolic) and for the models II and IV when I (C) and S(C) are linear. The results of these computations are shown in this section.
The graphs in this section have been made by means of Maple 9 (19). We substituted the explicit expression for R(t; D) into the right hand side of the differential equation. Since R = 0 at the peak time T max , we obtain an implicit relation between T max and D. For models I and III, this relation becomes
Maple 9 is then used to plot T max vs. D. For the models II and IV a similar relation is found. Case I. I (C) and S(C) are nonlinear. In this case I (C) and S(C) are given by Eqs. (3) and (4), or, in dimensionless variables, in Eq. (14a). In Fig. 5 we show graphs of T max , for the models I and III.
We see that in the models I and III, the peak time T max , increases with the drug dose D and drops with increasing κ.
The graphs in Fig. 5 look the same, and indeed, they are the same. To see this one substitutes the explicit solution of Eq. (13a) into Eq. (22) . One then finds that the constant α factors out, so that T max does not depend on α. Because the models I and III only differ by the sign in front of α it follows that
In Fig. 6 we show analogous graphs for models II and IV. Here we see demonstrated what we found in Eq. (17) for model IV: if α is small, then T max increases for small doses, whilst if α is larger, it will first decrease with increasing doses. In all four models, we see that eventually graph of T max for the model IV when κ = 2 and α = 1. In the linear model II we require that α D < 1 for it to make sense, i.e., we need D < 1/α. Large values of D are therefore uninteresting in this model. We observe that in the linear model IV, the peak time T max (D) is monotonically decreasing for all D > 0, in contrast to what we see in model IV when the drug mechanism function is nonlinear. In that case we know from Property E that T max (D) will eventually be increasing again when D becomes large.
QUALITATIVE ANALYSIS
In this section we prove Properties A-F of the response function R(t) and the Peak time T max . We shall do this by a careful analysis of the basic differential Eqs. (2a) and (2b), in which we view the solution R(t) as a curve or orbit in the (t, R)-plane, parametrized by the time variable t. We denote this curve by γ and write it as:
Since t > 0 and R > 0 this orbit γ will lie in the first quadrant. Figure 8 shows examples of orbits in the four different models. It is our objective in this section to investigate their characteristic shapes and their dependence on the parameters D, κ and α.
Throughout this section we use dimensionless variables, and, in order to keep the analysis simple and transparent, we assume that the drug function is given by Eq. (6), i.e., in dimensionless variables, 
C(t) = De
In the section on Genaralizations we shall discuss more general drug functions, including the Bateman function Eq. (7).
The Shape for the Response Curve
To be specific, we study the shape of the function R(t) for model III. For the other models the analysis is similar. The basic differential equation for this model is
For any given point in the (t, R)-plane, we can compute the sign of the right hand side of Eq. (24) and so decide whether at this point the orbit goes up or down, i.e., what the direction is of the orbit. When the right hand side vanishes, the orbit goes neither up nor down, but has a horizontal tangent. For convenience, we define the composite function
Then we see that at points in the (t, R)-plane where R and t satisfy the equation R = ϕ(t) the orbit has a horizontal tangent. The curve of these points is called the Nullcline and we denote it by :
In Fig. 8 
We now follow the orbit which starts with initial value R(0) = 1, i.e., at the point (t, R) = (0, 1) in the (t, R)-plane. Because
the orbit starts at a point which lies below . Therefore, initially the orbit goes up. It will continue to do so as long as it lies below , and so eventually it must hit the nullcline , and cross it, say at time t = T . Once it lies above it will go down again, and the question is: can it cross a second time? The answer is no.
Suppose, by way of contradiction, that it does cross again at some later time t 0 . Then
This contradicts Eq. (27) , and we may conclude that the orbit does not intersect the nullcline a second time. Thus, it has to stay above forever. We conclude that The graph of R(t) first goes up and then comes down again and decreases monotonically as t → ∞. Thus, we have shown that there exists a time T > 0 when the orbit crosses and that for all t > T, the orbit will be decreasing. Since it is bounded below by the line R = 1 it follows that R(t) tends to a limit, say L, i.e.
which, in turn, implies that R(t) → ∞ as t → ∞, a contradiction. Therefore, L = 1, and we conclude that
Conclusion. There exist a time T max > 0 such that R(t) increases on (0, T max ) and decreases on (T max , ∞), and R(t) → 1 as t → ∞.
This establishes the Properties A and B for the drug function given by Eq. (6) . A different proof of the above Conclusion was given in (12) .
Bounds of the Response
We derive bounds for the response R(t), Since the nonlinear drug mechanism functions I (C) and S(C) level off, and saturate, whilst the linear drug mechanism functions are unbounded for large doses, we obtain different types of bounds.
I. Nonlinear Drug Mechanism Functions
In this case we obtain bounds which are independent of the drug dose D. we consider model III in some detail and quote the bounds for the other models. In model III, the response R is governed by the equation
Let R(t) be the solution of the problem
Then, by a standard comparison lemma (17) (see also Appendix B),
In Fig. 9 we show a family of response curves for different drug doses, as well as the upper bound R(t). The corresponding bounds for the models I, II, IV are
In model II we have assumed that 0 < α < 1 and used the inequality
When α = 1, then in model II we can only say that R < κ and R(0) = 1 which means that
Similar bounds were given by Krzyzanski and Jusko (12) . Remark. Note that in the derivation of these bounds the particular form of the drug function has played no role.
II. Linear drug mechanism functions
If I (C) or S(C) depend linearly on C, the response in the models I and III depends linearly on D. To see this, we introduce a new dependent variable r (t):
We find that r (t) is a solution of the problem r = κ(e −t − r ), r (0) = 0 which can be given explicitly by
Hence the response R(t) is given by
It is clear that in these models the peak time does not depend on D. In the next section we shall show that
Remark. The analysis above reveals that in models I and III T max does not depend on α either if the drug mechanism functions are linear.
For the models II and IV we can establish bounds for R(t) as before; they are:
Note that these bounds depend on the drug dose D.
Bounds of the Peak Time
The bounds obtained above also yield lower bounds for the peak time T max . To see this, we return to the discussion of model III.
Let us denote the orbit which corresponds to the upper bound R(t) by γ . Since γ runs from the point (t, R) = (0, 1) to the point (∞, 1 + α) in the (t, R)-plane, and the nullcline runs from the point (0, S(0)) to the point (∞, 1), and S(0) > 1, it follows that the two curves must intersect. Since they are both monotone, γ increasing and decreasing, there exists precisely one point of intersection, say at t = T . Because γ lies below γ it follows that
We find that this lower bound also holds for the other models. In each of these models T (D) is defined as the unique time at which the orbit γ intersects the nullcline .
By studying the behavior of R(t) and H (C(t)) for large values t and D, we obtain the following limiting behavior of the function T (D) when H (C) is nonlinear:
T (D) ∼ 1 κ + 1 log
(D) as D → ∞ models I and III (39)
Similarly for the models II and IV, we find that as D → ∞,
Thus, we readily obtain lower bounds for the behavior of T max (D) as D → ∞. In the next section we shall see that these bounds are actually sharp.
A Wave Phenomenon
The solution graphs depicted in Fig. 3 exhibit a wave-like phenomenon: when the drug dose is increased, the decreasing part of the response curve translates to the right but essentially preserves its shape. The shift appears to be proportional to log(D).
To explain this phenomenon we inspect the equation for the response in model III:
The observations of Fig. 3 and Eq. (41) suggest we introduce a new temporal variable s which shifts with increasing drug dose D:
log(D) and φ D (s) = R(t; D)
In terms of these variables, Eq. (41) becomes
One can prove that in the limit as D → ∞,
for every fixed s ∈ (−∞, ∞), where is the solution of the problem
The details of the proof of this result are given in Lemma D.1. of Appendix D. There it is also shown that (s) is a decreasing function i.e.,
The fact that (s) is decreasing can be shown to imply that
For the proof of Eq. (46) we refer to Lemma D.2. of Appendix D.
The limiting behavior for R(t; D), obtained in (43), enables us to determine how the Area Under the Curve, AUC R , which is defined by
grows as D → ∞. Fig. 3 suggests that AU C R expands on the right where the response curve shifts to larger values of t, and this part of the curve is well approximated by the function (t − log(D)). Using this property one can show that
The details of the proof can be found in Lemma D.3. in Appendix D.
In the other models we encounter similar wave phenomena. They involve the following transitions:
The corresponding behavior of the Area Under the Curve, is given by
A special case is model II with α = 1. As we saw in Fig. 4 , there is also a wave like phenomenon here, but it is different from what we saw in Fig. 3 . In particular, we see that
We find that in this case the shape of R(t) tends to that of a triangle which grows like log(D) as D → ∞. From this limiting behavior of the response profiles we can conclude that in this case
and that
The proofs of these limits are given in the final part of Appendix D.
Conclusion. In the four nonlinear models, I, II (0 < α < 1), III and IV, AU C R (D) grows linearly with log(D) when D is large, and when α = 1 in model II, AU C R (D) grows quadratically with log(D)
. From the expressions above we see that we can determine the value of α from the rate of growth of AU C R (D), i.e., from the limiting slope of the graph of AU C R (D) versus log(D), (when 0 < α < 1 in model II) . These results were also established, by different means in (12) and (14) .
Remark. When in model III, the drug mechanism function is linear, then it follows at once from Eq. (33) that AU C R (D) increases linearly with D.
Dependence on κ and α
Although the prime focus in this paper is on the dependence of T max on the drug dose D, we make a few observations about the dependence of T max on the ratio κ of the fractional turnover rate k out and the elimination rate k in the drug function, and how it depends on the parameter α, which stands for I max or E max .
Dependence on κ
We see from the fundamental equations (13a) and (13b) that if κ is small, then R(t) will vary slowly with time. This implies the following property:
Property G1. Let D and α be fixed. Then
To see this we consider Eq. (13a) for model III, i.e., with H (C) = S(C). Since R > 1 it follows that R (t) < κ{S(C(t)) − 1} < κ{S(D) − 1} and hence

R(t) < 1 + κ{S(D) − 1}t
At t = T = T max we therefore have
which implies that T → ∞ as κ → 0, as asserted. On the other hand, when κ is large we have:
Property G2. Let D and α be fixed. Then
We explain this for the models I and III, and we write Eq. (13a) as
Note that initially, the right hand side is given by
When ε = 1/κ is small, this implies that R(t) jumps quickly from its initial value R(0) = 1 to the value H (D) and then follows the monotone graph of H (C(t) ). This means that T max , will be small when κ is large, and tends to 0 as κ → ∞.
For the models II and IV the argument is similar.
Dependence on α
We have seen that in the models I and III, T max does not depend on α.
As to the models II and IV, if H (C) is linear, then α appears as a factor of D. Hence, in this case
This means that if α increases, then the graph of T max (D; α) shifts to the left, i.e., for a given value of D, the peak time T max will become larger when the graph of T max is increasing and it will become smaller when the graph of T max is decreasing.
If H (C) is nonlinear, the influence of I C 50 /EC 50 or α on T max is more complex. However, we see from Eq. (17) and Eq. (18) that when α increases, then T max will become smaller, both for small and for large values of the dose D.
ASYMPTOTIC ANALYSIS
Whereas in the previous section we discussed a series of mainly qualitative properties of the response curve R(t) and the peak time T max , in this section we establish quantitative results about the peak time, for small and large drug doses. For small doses D, we use a standard perturbation argument (26) , expanding R(t; D) and the drug mechanism function H (C) in a series of increasing powers of D, while for large doses, we use an asymptotic analysis of the explicit solution of the differential equations underlying the different models.
Throughout this section we use the dimensionless variables introduced in Eq. (11) and we assume that the drug function C(t) is given by Eq. (6).
Small Doses
We have seen that for all the models I-IV, nonlinear as well as linear,
We give a proof of this limit for the nonlinear model III. For the other models the proof can be given in a similar manner. We expand the function R(t; D) and the function S(C) in increasing powers of D. Since if D = 0, then R is given by the equilibrium state R = 1, this expansion must be of the form
For the drug mechanism function (see (3.4a)) we obtain
We substitute these expansions into Eq. (2a) for R:
where primes denote differentiation with respect to time t. Equating the coefficients of D and D 2 to zero we obtain
Remembering that R(0; D) = 1, and hence r 1 (0) = 0 and r 2 (0) = 0, we find for r 1 and r 2 :
and
At the time T max of maximal response, we have
Hence, in the limit as D → 0, we have r 1 (T max (0)) = 0. We can use (56a) to compute T max (0), and we find that T max (0) = T 0 , where T 0 is given in (52).
To determine whether T max (D) increases or decreases when a small dose is administered, we expand T max (D) in powers of D, writing
Plainly, if T 1 > 0 then a small dose increases T max and if T 1 < 0 a small dose leads to a drop T max .
We continue with the analysis of the nonlinear model III and substitute the expansion Eq. (58) into Eq. (57). This yields
Since r 1 (T 0 ) = 0, this implies that
From (56a) we deduce that r 1 (T 0 ) = 0, so that we may conclude that
With the expression for r 1 (t) and r 2 (t) from (56) we can now compute T 1 , and we find that
where T 0 = T 0 (κ) has been defined in Eq. (52). We find that L 1 (κ) > 0 for all κ > 0, so that irrespective of the value of κ, the response is delayed when a small dose is given. For the nonlinear model I we find the same value of T 1 .
For the nonlinear models II and IV we find
Here the plus sign applies to model II and the minus sign to model IV. We find that L 2 (κ) > 0 for all κ > 0.
For the linear models I and III, T 1 = 0, and for the linear models II and IV we find exactly as in the nonlinear models,
the plus sign for model II and the minus sign for model IV.
Large Doses
We first discuss the case when H (C) is nonlinear, and then when it is linear.
I. Nonlinear Drug Mechanism Function
We recall from the lower bounds derived in Section 5.3 that in all four models
for some positive constants K and D 0 . However, in Section 5.4, and in Lemma D.2. in Appendix D, we saw that
This means that K ≤ 1.
In this subsection, we derive more precise estimates, and we first consider model III. We use the explicit expression for the solution, which is found to be
Since R (T max ) = 0, we obtain upon substitution into the differential equation
where we have written T = T max . In what follows we shall often omit the subscript "max". Because of our preliminary estimate Eq. (60), we have
Therefore, we may expand the integrand in Eq. (61) to obtain
Expanding the left hand side as well, we end up to leading order,
In model I the function T max (D) is the same as in model III (cf. Section 4). In models II and IV the line of reasoning is the same, but the formulas are a little more complex. For these two models we find that as D → ∞,
II. Linear Drug Mechanism Function
Since in the case of inhibition, when H (C) = 1 − αC, the concentration is bounded above by 1/α, we need only discuss model IV. In this model we have
We scale the variables and write
Equation (65) then becomes
This initial value problem can be solved explicitly, and we find that
We write S = α DT max . Since ρ (s) = R (t) it follows that ρ (S) = 0, and hence, by (67), that
Expanding both sides of Eq. (70) in powers of ε, we finally end up with
Returning to the original variables we find that
Thus, in the linear model IV, in contrast to the other models, T max (D) → 0 as D → ∞.
GENERALIZATIONS
We present two generalizations of the turnover model discussed in the earlier sections.
(a) We generalize the drug function C(t) to a function which is no longer monotone. Specifically we discuss the Bateman function
(b) We investigate a turnover model which involves a nonlinear elimination term which is bounded:
as discussed in (21) and (22) .
For both generalizations we investigate the implications for Property A and Property B.
The Drug Function
Since the drug function defined in Eq. (7) satisfies the conditions of Property A, we may focus on Property B. We shall show that this property continues to hold. As with many of our results, this is was known (cf. (13)), but here we present a different proof. We give it for model III, but for the other models it is similar.
We study the initial value problem
The nullcline is given by
Since C(0) = 0 and C(t) → 0 as t → ∞, it follows that
Thus, since d S/dC > 0 and C(t) increasing and then decreasing, so is ϕ.
As regards the orbit, we have
where we have used Property A. An elementary computation shows that
Hence, the orbit starts out below the nullcline . The vector field is such that the orbit will go up as long it lies below the nullcline. Because we know that the orbit eventually drops down to the initial value again, it has to cross . This can only happen at a point where ϕ(t) ≤ 0. Once it has crossed , the orbit must stay above and the proof is completed as in Section 5.
Remark . In the proof of Property B given above, we have only used the fact that C(t) first increases and then decreases. Thus, it is clear, that Property B holds for any drug function, which is either decreasing or first increasing and then decreasing.
A Nonlinear Turnover Model
As an example of a nonlinear turnover model we consider the equation
i.e., we consider a nonlinear generalisation of model III, where S(C) is defined in Eq. (4). To keep the analysis transparent we use the simple drug function defined in Eq. (6).
As a first step, we look for a stationary solution. In the absence of a drug, we expect the system to be at a rest state R 1 . We deduce from Eq. (73) that R 1 must be a root of the equation
where we have used the fact that S(0) = 1. An elementary computation shows that
It is evident that R 1 needs to be positive. Therefore we must require that
Assuming that prior to administration of the drug, the system is at rest, we impose the initial condition:
Proceeding as in the proof of Property A given in Section 5, we can prove the following analogue of this property: Property A * . Let R(t) be the solution of Problem (73), (75) and let C(t) be given by Eq. (6). Then
R(t) → R 1 as t → ∞
Next, let us turn to Property B which deals with the shape of the graph of R(t). Again, a key role is played by the nullcline , i.e. the curve along which d R/dt = 0. Here it is given by the equation
Because R needs to be positive, the nullcline is well defined as long as R 0 S(C(t)) < 1. We distinguish two cases:
Because C(t) < D for all t > 0 it follows that in this case R 0 S(C(t)) < 1 for all t > 0, so that is defined for all t > 0.
Case B. R 0 S(D) > 1. Since C(t) → 0 monotonically, and R 0 S(0) = R 0 < 1, there exists a unique time τ > 0 such that R 0 S(C(τ )) = 1. Then R 0 S(C(t)) < 1 on the interval τ < t < ∞, on which is now well defined. Note that ψ(t) → ∞ as t → τ .
Differentiating the expression for ψ we find that
Thus the nullcline is a strictly decreasing curve.
Let us now follow the orbit γ . At the starting point t = 0, we have
Thus, in Case A the orbit starts below i.e., at a point where d R/dt > 0. As in the linear turnover model, γ hits the nullcline and will cross it precisely once. In Case B, any orbit will go up in the interval 0 ≤ t ≤ τ , and eventually hit the nullcline, cross it and drop down without crossing it a second time. Thus, in both cases γ has precisely one critical point, as asserted in Property B.
Remark . By similar arguments Properties A and B can be established for systems of the form
as long as the function f (R) is increasing for all R > 0.
DISCUSSION AND CONCLUSIONS
Pharmacodynamic analysis coupled to the concentration-time course of drugs in plasma, tissues or urine, has become a common approach/means in the drug discovery/development process. Both, industry and regulators appreciate the merit of not only documenting the pharmacokinetic characteristics of a new compound, but also the onset, intensity and duration of its response. In certain situations compounds with non-optimal pharmacokinetics can often be "rescued" by good pharmacodynamic properties. An example of this is the proton-pump inhibitor omeprazole, with a plasma half-life of less than an hour, but a half-life of response in the range of 15-20 hr in man (25) .
In order to make accurate and precise predictions of the onset, intensity and duration of the response one needs to understand the intrinsic behavior of the proposed model. Knowing the constraints of the model characteristics, it is also possible to design experiments accordingly, in order to challenge the model(s). In an attempt to elucidate the behavior of the basic turnover model, we have analytically studied the effect of different "shapes" of the drug mechanism functions (I (C) and S(C))-both nonlinear (saturating) and linear-on the response-time profile.
In particular we studied the effect of the drug function on the peak shift. Our analysis confirms that when the drug function I (C) or S(C) is nonlinear, then T max increases with increasing doses in all the four models we studied, with the exception of model IV. In this model the peak time T max drops for small doses when E max is large enough, and then increases as the doses become larger. If the drug function is linear, T max will either be independent of the dose (models I and III), decrease with increasing doses (model II) (α D < 1) or decrease with increasing doses (model IV).
By a qualitative study of the fundamental equation of the Indirect Response Model, we establish a priori bounds on the response function R(t), on the peak time T max , and on the area under the curve AU C R . We also show that in the nonlinear models T max and AU C R increase with increasing doses, in proportion to the logarithm of the drug dose. In all nonlinear models (0 < α < 1 in model II), we find that AU C R (D) increases linearly with log(D) when D is large. The parameter α in the drug mechanism function can be determined from the slope of the graph of AU C R (D) vs. log(D). We also establish how T max is affected by E max and I max and by the ratio of k out and the elimination rate constant k of the drug plasma concentration.
We find that this qualitative approach, based on ideas from the theory of dynamical systems offers a powerful and conceptually attractive method for analyzing the four Indirect Response Models and conjecture that it will be an important tool in the analysis of more complex pharmacodynamic models.
The overall conclusion we can draw from this analysis is that the cause of the peak shift with changing drug doses lies in the drug mechanism function (I (C) or S(C)), rather than the turnover function in its basic form, such as −k out R. This may be of some help in discriminating between drug effects and system effects and for deciding between distributional and turnover models.
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APPENDIX A. SYMBOLS AND DEFINITIONS
Pharmacokinetic Constants and Functions
Mathematical Definitions
A def = B the symbol A is defined by the expression B f (x) ∼ g(x) as f (x)/g(x) → 1 as x → ∞ (x → 0) x → ∞(0) f (x) = O(ω(x)) as there exist constants K > 0 and ξ >0 such x → ∞(0) that | f (x)| < K |ω(x)| as x > ξ (0 < x < ξ)
APPENDIX B. A COMPARISON THEOREM
We compare solutions of the following two initial value problems:
Theorem B.1. Let R(t) and R(t) be the solutions of respectively (B.1) and (B.2) Then
R(t) < R(t) for all t > 0
Proof. We denote the difference between the two solutions by u:
Then, by subtractiong (B.1) from (B.2) we find that u(t) is the solution of the following problem
Problem (B.3) can be solved explicitly, and we find that
Because f (s) > 0 it follows that u(t) > 0 for all t > 0. This means that R(t) > R(t), as asserted.
APPENDIX C. PROOF OF PROPERTY A
Whereas in Section 5, we proved Property A under the assumption that
here we shall prove this property assuming only that
We shall do this again for model III. For the other models the proof is similar. Suppose to the contrary that R(t) does not tend to R 0 as t → ∞. Since, by comparison, R(t) > R 0 for all t > 0, this implies that there exists a sequence of points {t n }, tending to infinity as n → ∞, and a constant δ > 0 such that
On the other hand there must be a sequence of points {τ n }, tending to infinity as n → ∞ such that
because if R(t) > R 0 +δ for t large enough, the differential equation would imply, in view of (C.1), that lim sup t→∞ R (t) ≤ −δ which means that R(t) → −∞ as t → ∞. This contradicts the fact that we know that R(t) > R 0 for all t > 0. Thus, the graph of R(t) would cross the line R = R 0 +δ at a sequence of points {τ n } which tends to infinity. However, if we put R = R 0 + δ into the differential equation, we find that
When we let t → ∞ in this equation we find that
so that the graph of R(t) can only cross the line R = R 0 + δ in the downward direction. This contradicts our observation that R(t) would be crossing this line an infinite number of times, and so proves the assertion.
APPENDIX D. PROOFS OF RESULTS IN SUBSECTION 5.4
Let φ D (s) be the solution of the problem
We shall first prove the following limit:
where is the unique solution of the equation
which satisfies the following conditions at s = ±∞:
The function (s) is a strictly decreasing for −∞ < s < ∞.
Proof. Observe that for any D > 0, where we have used the differential equation (D.3). Thus (s) is decreasing and bounded below. Therefore, it must tend to a limit as s → ∞, and this limit can only be 1.
A similar argument can be used to prove that (s) satisfies the limiting condition at s = −∞. In fact, we find that * (s) < (s) < 1 + α for all − ∞ < s < ∞ Using this inequality in equation (D.3) we conclude that 
